Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study
- 10 April 2009
- journal article
- research article
- Published by Springer Nature in International Journal of Hematology
- Vol. 89 (4) , 460-469
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin.2006
- Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive diseaseAnnals of Oncology, 2004
- Acute and Long-Term Toxicities Associated with Gemtuzumab Ozogamicin (Mylotarg®) Therapy of Acute Myeloid LeukemiaClinical Lymphoma, 2002
- Gemtuzumab Ozogamicin, A Potent and Selective Anti-CD33 Antibody−Calicheamicin Conjugate for Treatment of Acute Myeloid LeukemiaBioconjugate Chemistry, 2001
- Pharmacokinetics of Gemtuzumab Ozogamicin, an Antibody‐Targeted Chemotherapy Agent for the Treatment of Patients with Acute Myeloid Leukemia in First RelapseThe Journal of Clinical Pharmacology, 2001
- Impact of Age and Gender on the Pharmacokinetics of Gemtuzumab OzogamicinPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2001
- Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.2001
- Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cellsBlood, 2001
- Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate.1999
- Calicheamicin γ 1 I and DNA: Molecular Recognition Process Responsible for Site-SpecificityScience, 1989